Mapping out the Implications for Medicine and Agency Deference in the Mifepristone Cases

Name: Mapping out the Implications for Medicine and Agency Deference in the Mifepristone Cases
Start: 2024-04-11T12:00:00
End: 2024-04-11T13:00:00

Stakeholders and the media have engaged in robust conversations about the Mifepristone rulings’ impacts that extend beyond abortion to other FDA decisions regarding historical court deference to agency interpretation of statutes and regulations, approvals of products that may face political opposition, and access and coverage variations across states.

Watch on demand

In this CLE program, leading litigation and regulatory attorneys address the implications of the landmark mifepristone litigation for women’s health, life science companies, administrative law, and the future of healthcare in America.

Related events

Related Insights

Our insights